Onderzoeker
Annick Moens
- Disciplines:Endocrinologie en metabole ziekten, Gastro-enterologie en hepatologie, Ontdekking en evaluatie van biomarkers, Ontdekking en evaluatie van geneesmiddelen, Medicinale producten, Farmaceutica, Farmacognosie en fytochemie, Farmacologie, Farmacotherapie, Toxicologie en toxinologie, Andere farmaceutische wetenschappen
Affiliaties
- Translationeel Onderzoek van Gastro-enterologische Aandoeningen (TARGID) (Afdeling)
Lid
Vanaf1 aug 2017 → 11 okt 2021
Projecten
1 - 1 of 1
- Lange termijn veiligheid van het sequentieel gebruik van biologische therapieën in chronische inflammatoire darmziekten: onschadelijk of gevaarlijk?Vanaf1 aug 2017 → 24 sep 2021Financiering: FWO mandaten
Publicaties
1 - 10 van 11
- Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study](2022)
Auteurs: Annick Moens
Pagina's: 1428 - 1435 - Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre(2022)
Auteurs: Annick Moens, Nasim Sadat Seyed Tabib, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pagina's: 271 - 281 - LONG-TERM SAFETY OF THE (SEQUENTIAL) USE OF BIOLOGICAL THERAPIES IN INFLAMMATORY BOWEL DISEASES(2021)
Auteurs: Annick Moens, Marc Ferrante, Séverine Vermeire
- Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding(2020)
Auteurs: Annick Moens, Marc Ferrante
Pagina's: 27 - 42 - Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center(2020)
Auteurs: Annick Moens, Matthias Lenfant, Gert Van Assche, Séverine Vermeire, Ann Gils, Marc Ferrante
Pagina's: 628 - 634 - Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study(2020)
Auteurs: Annick Moens, C Janneke van der Woude, Mette Julsgaard, Evelien Humblet, Juliette Sheridan, Daniel C Baumgart, Cyrielle Gilletta De Saint-Joseph, Stephane Nancey, Jean-Francois Rahier, Peter Bossuyt, et al.
Pagina's: 129 - 138 - Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study(2019)
Auteurs: Annick Moens, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
Pagina's: 129 - 138 - Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades(2019)
Auteurs: Annick Moens, Bram Verstockt, Kathleen Machiels, Peter Bossuyt, Katrien Lagrou, Gert Van Assche, Séverine Vermeire, Marc Ferrante
Pagina's: 668 - 673 - Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab(2019)
Auteurs: Annick Moens, Karen van Hoeve, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
Pagina's: 12 - 18 - Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy(2017)
Auteurs: Marc Ferrante, Anthony de Buck van Overstraeten, Annick Moens, Gert Van Assche, Albert Wolthuis, Séverine Vermeire
Pagina's: 1353 - 1361